





# SEGURANÇA DO PACIENTE ALÉM DOS PROTOCOLOS BÁSICOS: PREVENÇÃO E MANEJO DO DELIRIUM

**Dra. Viviane Cordeiro Veiga**  
**Unidade de Terapia Intensiva – BP – A Beneficência Portuguesa de**  
**São Paulo**  
**Presidente do Comitê de Analgesia, Sedação e Delirium – AMIB**  
**Presidente SOPATI – Gestão 2022/23**




**Figure 1. Causes and Interactions of Pain, Agitation, and Delirium.**


# Delirium involves complex pathways...



# Delirium and Long-Term Cognitive Outcomes



# Delirium Duration & Mortality



A Be

Shehabi Y, et al. CCM 2010; 38:2311–2318

# Avaliação Delirium

Avaliação clínica convencional não tem a acurácia necessária para o diagnóstico do delirium

Avaliação por médicos não psiquiátricos subdiagnosticaram até  $\frac{3}{4}$  dos pacientes com delirium.

Não utilização de ferramentas estruturadas: erro diagnóstico em 75% Devlin et al. Crit Care Med 2007; 35(12): 2721-4.



# Tratamento

## Prevenção Primária:

- Correção distúrbios metabólicos/hipóxia
- Tratamento de infecções
- Estratégia de sedação nos pacientes sedados
- **Mobilização precoce**
- Evitar restrições no leito
- **Respeitar ciclo sono/vigília**
- Permitir utilização óculos e equipamentos auditivos, quando necessário

# **Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU**

[www.ccmjournal.org](http://www.ccmjournal.org) September 2018 • Volume 46 • Number 9



A Beneficência Portuguesa de São Paulo



# Avaliação da dor

Escalas de auto report: Avaliação numérica de dor (visual ou verbal)

Escalas de avaliação comportamental: BPS, BPS-NI e CPOT


Envolvimento da família no manejo da dor

Alteração dos sinais vitais (FC, FR, PA, Sat O2) não são válidos como indicadores de avaliação de dor e pode ser usado somente para iniciar avaliação.

**BPS**  
**(intubated patients)**

1 2 3 4


①



②




③




**BPS-NI**  
**(non-intubated patients)**

1 2 3 4


=



=



≠



①+②+③ = Total BPS value

from 3 (no) to 12 (maximum) pain behavior rated using the BPS



An initiative of the ABIM Foundation

## Critical Care Societies Collaborative - Critical Care



We help the world breathe  
PULMONARY - CRITICAL CARE - SLEEP




### Five Things Physicians and Patients Should Question

#### 4 Don't deeply sedate mechanically ventilated patients without a specific indication and without daily attempts to lighten sedation.

4

Many mechanically ventilated ICU patients are deeply sedated as a routine practice despite evidence that using less sedation reduces the duration of mechanical ventilation and ICU and hospital length of stay. Several protocol-based approaches can safely limit deep sedation, including the explicit titration of sedation to the lightest effective level, the preferential administration of analgesic medications prior to initiating anxiolytics and the performance of daily interruptions of sedation in appropriately selected patients receiving continuous sedative infusions. Although combining these approaches may not improve outcomes compared to one approach alone, each has been shown to improve patient outcomes compared with approaches that provide deeper sedation for ventilated patients.




2

#### Não usar sedação excessiva

Limitar o uso de sedação aos pacientes com indicação precisa, assim como utilizar a menor quantidade de sedativos possível, apenas com o objetivo de manter o conforto do paciente, utilizando escalas para avaliar sistematicamente a titulação das doses das drogas em uso, mostram melhores resultados nos desfechos clínicos.

# MONITORIZAÇÃO




REVIEW

## Comfort and patient-centred care without excessive sedation: the eCASH concept



Jean-Louis Vincent<sup>1\*</sup>, Yahya Shehabi<sup>2</sup>, Timothy S. Walsh<sup>3</sup>, Pratik P. Pandharipande<sup>4</sup>, Jonathan A. Ball<sup>5</sup>, Peter Spronk<sup>6</sup>, Dan Longrois<sup>7</sup>, Thomas Strøm<sup>8</sup>, Giorgio Conti<sup>9</sup>, Georg-Christian Funk<sup>10</sup>, Rafael Badenes<sup>11</sup>, Jean Mantz<sup>12</sup>, Claudia Spies<sup>13</sup> and Jukka Takala<sup>14</sup>


## Early Comfort using Analgesia, Minimal Sedatives and Maximal Humane care




# Estratégias de sedação

- Sedação alvo
- Sedação intermitente
- Sedação guiada por metas

Kaplan e Bailey, 2000




Olson et al., 2003



■ Sedação excessiva ■ Alvo ■ Sedação insuficiente

# Two-years survival



Balzer F, Weiß B, Kumpf O et al. Early deep sedation is associated with decreased in-hospital and two-year follow-up survival. *Critical Care*. 2105;19(1):197



## Early Sedation with Dexmedetomidine in Critically Ill Patients

Y. Shehabi, B.D. Howe, R. Bellomo, Y.M. Arabi, M. Bailey, F.E. Bass,  
S. Bin Kadiman, C.J. McArthur, L. Murray, M.C. Reade, I.M. Seppelt, J. Takala,  
M.P. Wise, and S.A. Webb


In ventilated, critically ill patients, does the use of dexmedetomidine as the primary sedative agent compared with usual sedative agents effect 90 day mortality?

74 ICUs in 8 countries (Australia, Ireland, Italy, Malaysia, New Zealand, Saudi Arabia, Switzerland, UK)

November 2013 to February 2018




**A Percentage of RASS Scores at Target -2 to +1**



**Daily No. of RASS Assessments**

Dexmedetomidine	6286	10,562	9405	8035	6858	5839	5018	4305	3734	3330	2931	2577	2290	2080
Usual care	6309	10,606	9659	8349	7180	6202	5364	4672	4064	3514	3101	2784	2538	2367

**B Patients with a Clinical Indication for Deep Sedation**




**No. at Risk**


Dexmedetomidine	1952	1915	1775	1551	1351	1151	991	849	747	645	583	515	453	407
Usual care	1963	1928	1798	1610	1384	1201	1045	921	798	698	613	550	496	463




### A Dexmedetomidine




### B Propofol



### C Midazolam



### D Fentanyl



#### No. at Risk

Usual care	1963	1928	1798	1610	1384	1201	1045	921	798	698	613	550	496	463
Dexmedetomidine	1952	1915	1775	1551	1351	1151	991	849	747	645	583	515	453	407

#### No. at Risk

Usual care	1963	1928	1798	1610	1384	1201	1045	921	798	698	613	550	496	463
Dexmedetomidine	1952	1915	1775	1551	1351	1151	991	849	747	645	583	515	453	407



	DEX (n – 1954)	USUAL CARE ( N- 1964)
NEUROMUSCULAR BLOCKADE N (%)	684 (35%)	692 (35.2%)
NMB FOR $\geq$ 2 CONSECUTIVE DAYS N (%)	265 (13.6%)	278 (14.2%)



# Escassez de recursos

SP: Hospitais apontam 'desabastecimento gravíssimo' de 'kit intubação'

## Funcionários de hospitais denunciam a falta de sedativos para intubação de pacientes com Covid no RJ

Pacientes são intubados sem sedação nos hospitais Albert Schweitzer, do Andaraí e da Posse. Ministério da Saúde justifica a falta do medicamento devido a empréstimos entre as unidades hospitalares.

Por **Diego Haidar, RJ1**

22/05/2021 12h54 · Atualizado há 5 meses



## Pacientes com Covid são amarrados a macas no Amazonas por falta de sedativo

Em um hospital público de Parintins, acabou o sedativo usado para intubação. A Defensoria Pública vai apurar a situação dos pacientes.

Por **Jornal Nacional**

22/02/2021 21h29 · Atualizado há 8 meses




PANDEMIA

## Anvisa facilita importações e regras para remédios de intubação e oxigênio

No que diz respeito ao registro de medicamentos utilizados para intubação, a Anvisa estabeleceu que esses medicamentos poderão ser comercializados excepcionalmente apenas com notificação à Anvisa, que é um registro simplificado



## Cenário de escassez



A Beneficência Portuguesa de São Paulo

10ml/h é igual?



# Mobilization = Less Delirium


<b>Variable</b>	<b>Intervention (n=49)</b>	<b>Control (n=55)</b>	<b>P-value</b>
ICU/Hosp Delirium Days	2 days	4 days	0.03
Time in ICU with Delirium	33%	57%	0.02
Time in Hosp. with Delirium	28%	41%	0.01




A Be



# Programa de Mobilização Precoce- Hospital BP



# Protocolo de Reabilitação Cognitiva Precoce Hospital BP



# Promoção sono

Should noise and light reduction strategies (vs not using these strategies) be used at night to improve sleep in critically ill adults?

We suggest using noise and light reduction strategies to improve sleep in critically ill adults.



ELSEVIER

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

## Journal of Clinical Anesthesia

journal homepage: [www.elsevier.com/locate/jclinane](http://www.elsevier.com/locate/jclinane)



### Original Contribution

Ketamine vs. haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial



182 pacientes

Cirurgia eletiva/emergência

Grupos: haloperidol, ketamina, haloperidol + keta, placebo

**NENHUM DOS 3 GRUPOS FOI SUPERIOR AO PLACEBO PARA PREVENÇÃO DE DELIRIUM.**



A Beneficência Portuguesa de São Paulo

ORIGINAL

# Haloperidol, clonidine and resolution of delirium in critically ill patients: a prospective cohort study



Lisa Smit<sup>1\*</sup>, Sandra M. A. Dijkstra-Kersten<sup>2</sup>, Irene J. Zaal<sup>2</sup>, Mathieu van der Jagt<sup>1</sup> and Arjen J. C. Slooter<sup>2</sup>



Haloperidol, clonidine or both in critically ill pts, cohort study (mixed ICU):

- reduced probabilities of [#delirium](#) resolution
- worse short-term outcomes = longer delirium duration, [#ICU](#)/hospital stay, length of MV
- no effect on ICU mortality


[#FOAMed](#) [bit.ly/2he4yuh](#)

# Effectiveness and Safety of an Extended ICU Visitation Model for Delirium Prevention: A Before and After Study

286 pacientes

Restrita (4.5h/d) x Estendida (12h/d)

Outcome primário: delirium



## Effectiveness and Safety of an Extended ICU Visitation Model for Delirium Prevention: A Before and After Study

**TABLE 2. Comparison of Outcomes Before and After Implementation of an Extended ICU Visitation Model**

Outcomes	Restricted Visitation Model (n = 141)	Extended Visitation Model (n = 145)	Unadjusted RR (95% CI)	p	Adjusted RR <sup>a</sup> (95% CI)	p
Primary outcome, n (%)						
Cumulative incidence of delirium	29 (20.5)	14 (9.6)	0.47 (0.26–0.85)	0.02	0.50 (0.26–0.95)	0.03
Secondary outcomes						
Duration of delirium/coma <sup>b</sup> (d), median (IQR)	3.0 (2.5–5.0)	1.5 (1.0–2.0)	0.48 (0.31–0.73)	0.001	0.61 (0.39–0.97)	0.03
Any ICU-acquired infection, n (%)	13 (9.2)	8 (5.5)	0.59 (0.24–1.44)	0.25	0.63 (0.24–1.66)	0.35
ICU-acquired pneumonia, n (%)	8 (8.5)	6 (4.1)	0.72 (0.25–2.10)	0.55	1.04 (0.34–3.15)	0.94
ICU-acquired bloodstream infection, n (%)	3 (2.1)	2 (1.3)	0.64 (0.10–3.87)	0.63	0.70 (0.11–4.24)	0.70
ICU-acquired urinary tract infection, n (%)	2 (1.4)	2 (1.3)	0.97 (0.13–6.90)	0.97	1.08 (0.15–7.71)	0.93
ICU mortality, n (%)	9 (6.3)	3 (2.1)	0.32 (0.08–1.21)	0.09	0.34 (0.09–1.26)	0.10
Length of ICU stay (d), median (IQR)	4.0 (2.0–6.0)	3.0 (2.0–4.0)	0.87 (0.78–0.98)	0.02	0.89 (0.79–0.99)	0.04

# Delirium

## *Modifiable Risk Factors*

The PADIS guidelines identify two modifiable risk factors for delirium: the administration of blood transfusions and the use of benzodiazepines [1]. Restricting blood

Acute Brain Dysfunction in the  
Critically Ill

Christoph  
Pratik P. P.  
E. Wesley  
*Editors*

role in the development of delirium [2]. Other modifiable risk factors for the development of delirium identified in the literature include the practice of sedating patients more than clinically necessary [3–6], use of physical restraints with resulting immobility [7–9], social isolation [7], sleep deprivation [10, 11], and environmental factors such as excessive light and noise [7, 12]. Finally, the maintenance of





COVID-19

# O que mudou nas UTIs com o COVID-19?

- ✓ O COVID-19 gerou um número imenso de casos simultâneos e de elevada gravidade.
- ✓ Um em cada 3 pacientes hospitalizados precisa de UTI.
- ✓ 50% usarão VM invasiva, com uma duração média de 8 dias.
- ✓ A combinação destes fatores fará com que um grande número de pacientes precisem ser sedados de modo prolongado.



**Uso de Suporte na Unidade e Principais Desfechos –  
Internações em UTI Adulto com Desfecho Hospitalar Atribuído**

Período: **01/03/2020 – 22/04/2022**

(consulta realizada em 23/04/2022)

Hospitais	SARI			COVID-19		
	Todos	Privados	Públicos	Todos	Privados	Públicos
Saídas do hospital	<b>280.761</b>	192.238	88.523	<b>210.356</b>	146.517	63.839
VNI	<b>33,7%</b>	36,1%	28,4%	<b>38,3%</b>	40,5%	33,0%
VM	<b>47,1%</b>	40,4%	62,3%	<b>49,1%</b>	42,9%	63,3%
VM (dias)*	<b>14,1</b>	15,2	12,5	<b>14,7</b>	15,7	13,1
VM > 7 dias	<b>53,2%</b>	56,4%	48,5%	<b>57,4%</b>	60,5%	52,5%


[www.utisbrasileiras.com.br](http://www.utisbrasileiras.com.br)

Acesso em 11.05.2022





COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)



# Utilização sedativos


- 5% UTI (1,4M)
- 50% em VM – 700k – utilizar sedativos

## Delirium in Patients with SARS-CoV-2 Infection: A Multicenter Study

Paola Rebora, MS,\* Renzo Rozzini, MD,<sup>†</sup> Angelo Bianchetti, MD,<sup>‡</sup> Paolo Blangiardo, MD,<sup>§</sup>  
 Alice Marchegiani, MD,<sup>§</sup> Andrea Piazzoli, MD,<sup>§</sup> Francesca Mazzeo, MD,<sup>†</sup> Giulia Cesaroni, MD,<sup>†</sup>  
 Anita Chizzoli, MD,<sup>‡‡</sup> Fabio Guerini, MD,<sup>‡</sup> Paolo Bonfanti, MD,<sup>§§</sup>  
 Alessandro Morandi, MD, MPH,<sup>\*\*††</sup> Bianca Faraci, MD,<sup>\*\*</sup> Simona Gentile, MD,<sup>\*\*</sup>  
 Claudio Bna, PhD,<sup>‡‡</sup> Giordano Savelli, MD,<sup>‡‡</sup> Giuseppe Citerio, MD,<sup>§</sup>  
 Maria Grazia Valsecchi, MS,\* Paolo Mazzola, MD,<sup>§§§</sup> and Giuseppe Bellelli, MD,<sup>§§§</sup> for the  
 CoViD-19 Lombardia Team

516 pacientes  
 Lombardia  
 Idosos

14% delirium admissão



Delirium on admission:	73	66	59	43	29	27	22	19	17	16	15
No delirium on admission:	443	417	341	274	209	173	147	123	101	79	68



ELSEVIER

Review article

# Neurological manifestations and complications of COVID-19: A literature review

**Table 1**

Comparison of Neurological complications and manifestations between the severely ill Chinese and French patient series.

Variable	Mao et al. [11]	Helms et al. [12]
Study design	Retrospective Chart review	Observational study
Total Number of cases	214	58
Number of seriously ill patients	88	58
Median Age (Years)	58.7	63
Neurological Involvement	45.5%	84%
Dizziness	19.3%	NR
Headache	17.1%	NR
Impaired consciousness	14.8%	NR
Hypogeusia	5.6%	NR
Hyposmia	5.1%	NR
Skeletal muscle injury	19.3%	NR
Simplified Acute Physiology Score II	NR	52
Agitation	NR	40 (69%)
Delirium as documented by CAM-ICU	NR	26 (65%)
Corticospinal tract signs	NR	39 (67%)
Dysexecutive syndrome at discharge	NR	14 (36%)
Ischemic stroke	5 (5.7%)	3/13 (23%)
Hemorrhagic Stroke	1 (1.13)	Nil
Leptomeningeal enhancement on MRI	NR	8/13 (62)
EEG	NR	1(8) diffuse bifrontal slowing

Foot Notes. CAM-ICU; Confusion assessment method in Intensive care unit, EEG; electroencephalogram, MRI; Magnetic resonance imaging, NR; Not reported.



## Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study



Brenda T Pun\*, Rafael Badenes\*, Gabriel Heras La Calle, Onur M Orun, Wencong Chen, Rameela Raman, Beata-Gabriela K Simpson, Stephanie Wilson-Linville, Borja Hinojal Olmedillo, Ana Vallejo de la Cueva, Mathieu van der Jagt, Rosalía Navarro Casado, Pilar Leal Sanz, Günseli Orhun, Carolina Ferrer Gómez, Karla Núñez Vázquez, Patricia Piñero Otero, Fabio Silvio Taccone, Elena Gallego Curto, Anselmo Caricato, Hilde Woien, Guillaume Lacave, Hollis R O'Neal Jr, Sarah J Peterson, Nathan E Brummel, Timothy D Girard, E Wesley Ely, Pratik P Pandharipande, for the COVID-19 Intensive Care International Study Group†

- Mechanical ventilation
- Use of restraints
- Benzodiazepine, opioid
- Vasopressor infusions
- Antipsychotics

were each associated with a higher risk of delirium the next day

(all  $p \leq 0.04$ )



A Beneficência Portuguesa de São Paulo

Lancet Respir Med 2021 Published Online January 8, 2021  
[https://doi.org/10.1016/S2213-2600\(20\)30552-X](https://doi.org/10.1016/S2213-2600(20)30552-X)





# The intensive care delirium research agenda: a multinational, interprofessional perspective

## What are some of the top study areas/trials to be done in the next 10 years?

1. Development and validation of objective tools for delirium screening/diagnosis in critically ill patients, e.g., electroencephalogram, computer-based apps
2. Understanding the pathophysiology of delirium and its relationship mechanistically to long-term cognitive decline
3. Development of new models to improve delirium phenotyping
4. Understanding the attributable risk of delirium on outcomes; going beyond associations to causal inferences
5. Elucidating the biomarkers of delirium and incorporation into predictive models

- MONITORIZAÇÃO
- ESTRATÉGIAS SEDAÇÃO – NÃO AOS BENZODIAZEPÍNICOS
- MOBILIZAÇÃO PRECOCE
- CICLO SONO/VIGÍLIA